Zentalis Pharmaceuticals, Inc. Common Stock Morgan Stanley 24th Annual Global Healthcare Conference

Thanks, Michael. As always, we really appreciate the invite and the time. Just to go toe-to-toe with disclosures, since that seems to be the flavor, I would hate to be remiss in reminding the audience that we will be making estimates and forward-looking statements. There are risks and uncertainties associated with those, and we encourage those listening to review our SEC filings. Now we both are squared away with our lawyers.

Absolutely. Would love to. Zentalis is a late-stage clinical development company focused on developing azenosertib, which is a WEE1 inhibitor. It's a small molecule. Our focus is in platinum-resistant ovarian cancer for patients who express high levels of a protein called Cyclin E1. We are currently conducting the DENALI trial. Part 2 of that trial is a trial intended to be registrational for an accelerated approval pathway in the U.S. In addition to that, we are also enrolling our ASPENOVA trial, which is the companion trial, which is a randomized controlled trial which supports accelerated approval but also converts to a global full approval.

Yeah. Very busy. We also are expanding in some earlier lines of ovarian, doing some proof of combination studies there that we're happy to talk about, and then very interested in furthering the development of azenosertib in other combinations and other tumor types, and all focused with the intent to bring the drug to as many patients as possible.

Sure. It's an exciting space. It's exciting for patients, but also for drug developers, because a lot of new opportunities. I think, overall, when you think about the totality of the work that's being done, it's really around targeted therapies, and in our case, around biomarker selected patient population where there is a high unmet need. Probably higher unmet need given the Cyclin E1 patients, certainly in the PROC setting, typically don't do as well, progress faster. So no targeted therapies for these patients, Cyclin E1 patients in the platinum-resistant space. And we think there's a clear advantage for a different modality. Azenosertib is an oral. It is not a chemotherapeutic agent, which is primarily, if not all, that's available to patients. And again, it's for this important biologically different selected population.

Yeah. A real advantage, we think, compared to maybe some other targeted agents that are coming along.

Yeah. Ingmar, do you want to talk about the characteristics of azenosertib then, compared to chemo? I think that would be helpful.

Yeah, no, happy to, Julie. Yeah, so, compared to most of the available chemotherapies out there, it is an oral therapy, right? Some oral chemotherapies out there, but not many, right? And it is differentiated due to its five on, two off schedule.

which is part of the, as we see good tolerability, and in terms of safety, it really is differentiated due to a lower rate of cytopenias, namely neutropenia, right? Other side effects include GI toxicities, but also to a lower degree. The third group of side effects is fatigue. Those overall, it is providing additional flexibility due to the oral route of administration. It is due to its schedule that has been developed across a large number of patients, actually over 1,000 now. Very well tolerated, yet efficacious. It is from primarily single agent chemotherapy, well-differentiated in terms of its toxicity profile, but also from the emerging players like ADCs or taxane regimen.

Yeah. And maybe just from a patient journey perspective.